We can’t show the full text here under this license.
Link between diabetes treatments that affect digestion hormones and thyroid cancer in US Medicare patients
Updated
Abstract
Essence
Among older US adults with type 2 diabetes, starting incretin-based therapy was not associated with higher 3-year risk than starting SGLT-2 inhibitors.
Evidence
A weighted Medicare new-user cohort compared 73,388 GLP-1RA users and 106,274 DPP-4 inhibitor users with SGLT-2 inhibitor users, finding adjusted 3-year risk differences of -23 and -2 thyroid cancer cases per 10,000, respectively, with confidence intervals crossing zero.
Caveat
Median treatment lasted only 0.82-1.15 years, so the study offers short-term reassurance but cannot rule out long-term or subtype-specific thyroid cancer risks.
Simplified
Key numbers
-23 per 10 000
Adjusted 3-Year for vs.
Adjusted cumulative incidence difference for
-2 per 10 000
Adjusted 3-Year for vs.
Adjusted cumulative incidence difference for